ILS, a Triangle-based provider of clinical and manufacturing services to life science firms, is expanding its presence in North Carolina – through an acquisition.
The 27-year-old firm, which employs some 170 people, said Friday that it has acquired “key” assets of Beckman Coulter Genomics in Morrisville.
As a result, ILS formed a new venture called ILS Genomics.
It’s the first acquisition made by ILS.
The deal adds molecular genotyping, gene expression and biologics product safety testing services to the ILS menu of offerings. ILS already provides toxicology, histopathology, genetic toxicology, and environmental and information sciences.
“We are very pleased to add the top flight team from ILS Genomics,” said Dr. TK Rao, the chairman and founder of ILS, in a statement. “With this purchase, ILS continues its investment in people and innovative technology and is proud to enhance Research Triangle Park, NC as the leading bio/pharmaceutical hub in the United States.”
The genomics facility meets Good Laboratory Practices and current Good Manufacturing Practices standards as well as European and Australian regulatory requirements.
Sam Tetlow, the chief business officer of ILS, will head up genomics operation.
ILS Genomics numbers 23 of the world’s top 25 pharmaceutical clients among its clients.